Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00325351 |
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Condition | Intervention | Phase |
---|---|---|
Ovarian Neoplasms |
Drug: SH-Y03757A (ZK-Epothilone; ZK-219477) with carboplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer |
Enrollment: | 45 |
Study Start Date: | August 2006 |
Study Completion Date: | March 2009 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: SH-Y03757A (ZK-Epothilone; ZK-219477) with carboplatin
Chemotherapy for recurrent ovarian cancer
|
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc. Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Tucson, Arizona, United States, 85724 | |
United States, Arkansas | |
Little Rock, Arkansas, United States, 72205 | |
United States, California | |
Bakersfield, California, United States, 93309 | |
San Diego, California, United States, 92128 | |
La Jolla, California, United States, 92093 | |
United States, Georgia | |
Savannah, Georgia, United States, 31404 | |
United States, Indiana | |
South Bend, Indiana, United States, 46617 | |
United States, Maryland | |
Baltimore, Maryland, United States, 21204 | |
United States, New Mexico | |
Albuquerque, New Mexico, United States, 87131 | |
United States, North Carolina | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Cleveland, Ohio, United States, 44109-1998 | |
United States, Oklahoma | |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, Tennessee | |
Knoxville, Tennessee, United States, 37920 | |
United States, Virginia | |
Roanoke, Virginia, United States, 24014 | |
Canada, Alberta | |
Calgary, Alberta, Canada, T2N 4N2 | |
Canada, Ontario | |
Toronto, Ontario, Canada, M4N 3M5 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Healthcare Pharmaceuticals Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | 91476, 307979 |
Study First Received: | May 11, 2006 |
Last Updated: | July 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00325351 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Ovarian cancer Ovarian neoplasms, epithelium |
Ovarian Neoplasms Gonadal Disorders Epothilones Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Antimitotic Agents Ovarian Diseases |
Carboplatin Recurrence Genital Diseases, Female Tubulin Modulators Ovarian Cancer Endocrinopathy Endocrine Gland Neoplasms |
Ovarian Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Gonadal Disorders Epothilones Mitosis Modulators Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Antimitotic Agents |
Ovarian Diseases Carboplatin Pharmacologic Actions Adnexal Diseases Genital Diseases, Female Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Endocrine Gland Neoplasms |